Gastric Cancer Diagnostics Market Outlook 2035: Global Market Size, Forecast Growth to USD 6.9 Billion, Key Drivers, Leading Players, Investment Trends, and Regional Opportunities

The global gastric cancer diagnostics market continues to accelerate as the demand for early cancer detection increases across healthcare systems worldwide. Valued at US$ 3.5 billion in 2024, the market is projected to nearly double to US$ 6.9 billion by 2035, expanding at a compelling CAGR of 6.4% from 2025 to 2035. This expansion is strongly driven by a rising burden of gastric cancer, growing risk factors such as Helicobacter pylori infections, obesity, smoking, and significant advancements in endoscopy, imaging, and molecular diagnostic technologies.

Discover Market Opportunities - Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86864

Market Size

In 2024, the gastric cancer diagnostics market reached US$ 3.5 billion, marking a strong recovery and expansion driven by improved healthcare access globally. With rapid adoption of high-resolution imaging tests, biomarker-based diagnostics, and AI-powered decision support tools, the market is set to reach US$ 6.9 billion by 2035. This forecast reflects a rising demand for minimally invasive testing, adoption of precision oncology, and government-backed cancer screening initiatives.

Market Overview

Gastric cancer remains one of the leading causes of cancer-related deaths worldwide. Early-stage diagnosis significantly improves survival rates, making timely and accurate diagnostic methods a critical component of cancer control programs. Technologies such as CT scans, MRI, PET imaging, endoscopy, liquid biopsies, and molecular biomarker testing have become cornerstones of clinical workflows.

In 2024, imaging tests held a dominant market share of 74.8%, reflecting their role as the first-line diagnostic and staging tools. Regionally, North America accounted for 45.7% of global revenues, supported by high healthcare spending, strong insurance coverage, and widespread availability of cutting-edge diagnostic devices.

The market continues to evolve toward patient-centric diagnostic pathways, including decentralized testing, rapid molecular assays, and AI algorithms that improve interpretation accuracy and reduce diagnostic delays. Integration of molecular diagnostics helps clinicians identify HER2, MSI/MMR, PD-L1 expression, and emerging genomic markers that support personalized treatment decisions.

Key Market Growth Drivers

Rising Global Prevalence of Gastric Cancer

Rising gastric cancer incidence is one of the primary drivers increasing demand for diagnostic tests. Growing consumption of processed foods, higher obesity rates, H. pylori infections, smoking, alcohol consumption, and genetic predisposition are contributing to a larger patient pool requiring early screening.

Governments and healthcare systems are expanding national cancer screening programs, increasing adoption of imaging and endoscopic diagnostics. Hospitals are investing in high-resolution endoscopy systems, advanced pathology services, and molecular testing to manage growing caseloads.

Technological Advancements in Diagnostic Tools

Ongoing technological innovations remain central to market expansion:

High-resolution endoscopy, narrow-band imaging, and endoscopic ultrasound have improved early detection accuracy.

Molecular diagnostics-including PCR, NGS, and immunohistochemistry-enable biomarker detection for HER2 and PD-L1.

AI-powered systems assist in image interpretation, reducing human error and improving diagnostic precision.

Liquid biopsies provide minimally invasive alternatives for biomarker detection and disease monitoring.

These advancements improve workflow efficiency, accuracy, and the ability to diagnose gastric cancer at earlier stages.

Growing Integration of Diagnostics into Preventive Healthcare
The shift toward value-based healthcare encourages early detection to prevent worse outcomes and reduce long-term treatment costs. Insurance providers increasingly reimburse diagnostic tests, making advanced diagnostics more accessible in both urban and semi-urban areas. Public and private investments in preventive oncology are expanding diagnostic capabilities in hospitals and diagnostic centers.

Analysis of Key Players - Key Player Strategies

The competitive landscape is characterized by global leaders and innovative emerging companies. Key players include:

Abbott, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, MiRXES Pte Ltd., Endofotonics Pte Ltd., Hipro Biotechnology Co.,Ltd., Fulgent Genetics, NeoGenomics Laboratories, Samsung Medison Co., Ltd., Natera, Inc., Randox Laboratories Ltd., GE HealthCare, Koninklijke Philips N.V, CANON MEDICAL SYSTEMS CORPORATION, and Promega Corporation.

Their strategies revolve around:

Expanding diagnostic product portfolios with new imaging and molecular testing solutions.

Establishing partnerships with hospitals, diagnostic chains, and government health agencies.

Enhancing distribution networks in emerging markets.

Conducting real-world evidence studies to strengthen reimbursement approvals.
Investing in clinician training and awareness campaigns to increase adoption.
Developing AI-powered diagnostic algorithms to support decision-making.
Emerging companies focus heavily on precision diagnostics, biomarker discovery, and point-of-care innovations to differentiate in the competitive landscape.

Market Challenges & Opportunities

Challenges

High cost of advanced diagnostic technologies limits adoption in low-income regions.

Shortage of trained endoscopists and pathologists creates diagnostic delays.
Regulatory hurdles for new diagnostic tests slow commercialization timelines.
Variability in reimbursement policies makes market penetration difficult in certain regions.

Opportunities

AI-driven imaging tools to automate diagnostic interpretation and reduce human error.
Liquid biopsy innovations enabling non-invasive early detection.
Expansion into emerging markets such as Southeast Asia, Latin America, and Africa.
Public-private partnerships to strengthen national cancer screening programs.
Personalized oncology diagnostics, including genomic and proteomic profiling.

Explore Strategies & Trends - Request Full Report Access - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86864

Key Player Strategies

Companies are increasingly focusing on:

Launching integrated diagnostic platforms that combine imaging, pathology, and molecular testing.
Adopting subscription-based diagnostic models for affordability.
Enhancing R&D to develop next-generation endoscopic technologies.
Expanding manufacturing capabilities to meet rising global demand.
Collaborating with AI companies to automate diagnostic workflows.
These strategies aim to strengthen global presence and accelerate innovation.

Recent Developments

In August 2025, Akeso, Inc. announced the enrolment of the first patient in the phase III pivotal clinical trial, COMPASSION-33, for evaluation of a first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with chemotherapy, for the perioperative treatment of resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.
In March 2024, Astellas Pharma Inc. announced that the company received approval for VYLOYTM (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody, from Japan's Ministry of Health, Labour and Welfare (MHLW), for the treatment of CLDN18.2-positive, unresectable, advanced or recurrent gastric cancer.

Investment Landscape and ROI Outlook

Investment in gastric cancer diagnostics is rising due to the growing global emphasis on early cancer detection. Venture capital firms, private equity investors, and government-funded cancer initiatives are allocating resources to:

Precision oncology diagnostic startups
AI-driven imaging solutions
Molecular testing and biomarker discovery platforms
Decentralized diagnostic technologies

ROI remains strong, particularly in advanced imaging and molecular diagnostics, where recurring demand, reimbursement improvements, and technological advancements generate long-term revenue streams. The shift toward personalized medicine further enhances investment attractiveness.

Market Segmentations

Diagnostic Test Type

The market includes imaging tests, molecular tests, biopsies, and tumor marker tests. Imaging tests remain the dominant segment, supported by clinical necessity for tumor staging and surgical planning.

Disease Type

Adenocarcinoma represents the most frequently diagnosed gastric cancer type globally, followed by GIST and neuroendocrine tumors.

End-User

Hospitals account for the largest share of diagnostic procedures, followed by diagnostic centers and academic institutes.

Regional Analysis

North America leads the market with 45.7% share due to advanced healthcare systems and favorable reimbursement.

Europe follows with strong research infrastructure and widespread screening adoption.

Asia Pacific is the fastest-growing region due to rising gastric cancer cases in China, Japan, and South Korea.

Latin America and Middle East & Africa present significant growth opportunities through healthcare modernization.

Why Buy This Report?

Provides comprehensive insights into global and regional market trends.
Includes detailed forecast analysis to 2035 with verified market values.
Offers in-depth profiling of key players with strategic insights.
Covers technological advancements shaping the future of gastric cancer diagnostics.
Supports investors, policymakers, and healthcare providers with actionable data for decision-making.

FAQs

How big was the global gastric cancer diagnostics market in 2024?
The global gastric cancer diagnostics market was valued at US$ 3.5 billion in 2024.

How large will the market be by 2035?
The industry is projected to reach US$ 6.9 billion by 2035.

What factors are driving market growth?
Key drivers include rising gastric cancer incidence, H. pylori prevalence, obesity, smoking, technological advancements, and increasing adoption of national screening programs.

What is the CAGR of the market?
The market is anticipated to expand at a CAGR of 6.4% from 2025 to 2035.

Who are the major players?
Prominent players include Abbott, Agilent Technologies, Roche, MiRXES, Endofotonics, Fulgent Genetics, NeoGenomics, Samsung Medison, Natera, GE Healthcare, Philips, Canon Medical, and Promega Corporation.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=86864<ype=S

Explore Latest Research Reports by Transparency Market Research:

Particle Therapy Market: https://www.transparencymarketresearch.com/particle-therapy-market.html

Global Collagen and Gelatin MarketL https://www.transparencymarketresearch.com/collagen-and-gelatin-market.html

Nasal Irrigation Market: https://www.transparencymarketresearch.com/nasal-irrigation-market.html

Contact Us:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

This release was published on openPR.